KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2025)

Amneal Pharmaceuticals has reported Equity Average over the past 8 years, most recently at -$90.4 million for Q4 2025.

  • Quarterly results put Equity Average at -$90.4 million for Q4 2025, up 10.89% from a year ago — trailing twelve months through Dec 2025 was -$90.4 million (up 10.89% YoY), and the annual figure for FY2025 was -$90.0 million, down 101.74%.
  • Equity Average for Q4 2025 was -$90.4 million at Amneal Pharmaceuticals, up from -$111.2 million in the prior quarter.
  • Over the last five years, Equity Average for AMRX hit a ceiling of $387.2 million in Q1 2022 and a floor of -$122.3 million in Q2 2025.
  • Median Equity Average over the past 5 years was $147.6 million (2023), compared with a mean of $119.2 million.
  • Peak annual rise in Equity Average hit 10.89% in 2025, while the deepest fall reached 453.14% in 2025.
  • Amneal Pharmaceuticals' Equity Average stood at $375.1 million in 2021, then crashed by 49.57% to $189.1 million in 2022, then plummeted by 53.94% to $87.1 million in 2023, then crashed by 216.41% to -$101.4 million in 2024, then increased by 10.89% to -$90.4 million in 2025.
  • The last three reported values for Equity Average were -$90.4 million (Q4 2025), -$111.2 million (Q3 2025), and -$122.3 million (Q2 2025) per Business Quant data.